Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 2Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myeloid, Acute 73Myelodysplastic Syndromes 34Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Biphenotypic, Acute 17Hematologic Neoplasms 14Burkitt Lymphoma 14Myeloproliferative Disorders 13Leukemia, Myelomonocytic, Chronic 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 7Myelodysplastic-Myeloproliferative Diseases 6Multiple Myeloma 6Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Primary Myelofibrosis 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Hairy Cell 3GATA2 Deficiency 3

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
GATA2 Deficiency × Specimen Handling × Other hematologic neoplasm × Clear all
NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Recruiting
54 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06357182 2025-08-12

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

GATA2 Deficiency, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡